Skip to main content

Table 3 Distribution of VDR1 ApaI polymorphism across different case-controls studies

From: Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Author

Year

Country

Renal disease type

Genotypes

C-allele frequency

Cases

Control

AA

AC

CC

AA

AC

CC

Cases

Controls

Wang [23]

2016

China

ESRD

206

207

39

502

350

52

0.32

0.25

Cakir [20]

2016

Turkey

NL

43

40

15

26

34

10

0.36

0.39

Ghorbanihaghjo [29]

2014

Iran

CH

10

23

13

16

16

11

0.53

0.44

Martin [24]

2010

Ireland

DN

185

323

147

200

322

152

0.47

0.46

Ozkaya [16]

2003

Turkey

NL

13

30

21

4

50

36

0.56

0.68

Zhang [28]

2012

China

DN

19

89

74

11

65

46

0.65

0.64

Han [14]

2015

China

DN

2

50

56

18

80

82

0.75

0.68

Nosratabadi [7]

2010

Iran

DN

9

64

27

9

63

28

0.59

0.60

Goknar [15]

2016

Turkey

NL

24

42

12

11

40

9

0.42

0.48

Tripathi [21]

2010

India

ESRD

80

116

62

171

324

74

0.47

0.41

Mittal [22]

2010

India

NL

43

70

12

57

71

22

0.38

0.38

Gunes [17]

2006

Turkey

NL

40

58

12

59

72

19

0.37

0.37

Aykan [19]

2015

Turkey

NL

14

5

145

12

0

155

0.90

0.93

  1. The following studies were shown to have deviation from HWE: Ozkaya et al. (p = 0.03), Nosratabadi et al. (p = 0.009), Goknar et al. (p = 0.03), Tripathi et al. (p < 0.0001) and Aykan et al. (p < 0.0001)
  2. ESRD end stage renal disease, NL nephrolithiasis, CH chronic hemodialysis, DN diabetic nephropathy